Vaxart(VXRT)
SOUTH SAN FRANCISCO, CA
BiotechnologyFocus: Oral Vaccines
Vaxart is a life sciences company focused on Oral Vaccines.
Infectious DiseasesVaccines
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
VXA-A1.1 Oral Vaccine
InfluenzaClinical Trials (1)
NCT01688297Safety Study of an Oral Vaccine to Prevent Seasonal Influenza
Phase 1VXA-RSV-f Tablets
Respiratory Syncytial Virus (RSV)Clinical Trials (1)
NCT02830932Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)
Phase 1Norwalk GI.1 Virus
Norovirus InfectionClinical Trials (1)
NCT03721549Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model
Phase 1VXA-G1.1-NN
Norovirus InfectionClinical Trials (1)
NCT03897309Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines
Phase 1VXA-G1.1-NN
Norovirus GastroenteritisClinical Trials (1)
NCT02868073Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine
Phase 1VXA-A1.1
Seasonal InfluenzaClinical Trials (1)
NCT01761123Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum
Phase 1VXA-CoV2-1
Covid19Clinical Trials (1)
NCT04563702Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
Phase 1CS-8958 formulated as dry powder
InfluenzaClinical Trials (1)
NCT00311714Safety, Tolerability and Pharmacokinetic Study of Biota-CS-8958
Phase 1BTA-C585 oral capsules
PharmacokineticsClinical Trials (1)
NCT02668367Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers
Phase 1VXA-GI.1.NN
Norovirus InfectionsClinical Trials (1)
NCT04854746Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine
Phase 1VXA-G1.1-NN
Norovirus InfectionsClinical Trials (1)
NCT06944717A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old
Phase 1CS-8958
InfluenzaClinical Trials (1)
NCT00995826Safety, Tolerability and Pharmacokinetic Study of Multiple Doses of CS-8958
Phase 1ND1.1
Avian InfluenzaClinical Trials (1)
NCT01698060Immunogenicity of ND1.1 by Delivery Directly to the Ileum
Phase 1ND1.1
Avian InfluenzaClinical Trials (1)
NCT01335347Safety Study of an Oral Vaccine to Prevent Avian Influenza
Phase 1BTA-C585 oral capsules
PharmacokineticsClinical Trials (1)
NCT02558413Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers
Phase 1Vapendavir 300 mg tablet
HealthyClinical Trials (1)
NCT02101866A Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Formulations in Healthy Volunteers
Phase 1Laninamivir octanoate
AsthmaClinical Trials (1)
NCT02022761Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic Asthma
Phase 1Midazolam 5mg Syrup
Drug-Drug Interaction Healthy VolunteersClinical Trials (1)
NCT02204501A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers
Phase 1VXA-BYW.10
Seasonal Influenza BClinical Trials (1)
NCT02547792Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults
Phase 1VXA-G1.1-NN Oral Vaccine
Norovirus GastroenteritisClinical Trials (1)
NCT03125473Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers
Phase 1CS-8958 formulated as dry powder
InfluenzaClinical Trials (1)
NCT00657111CS-8958 Single Inhaled Dose in Elderly
Phase 1VXA-A1.1 H1 Tablet Vaccine
Seasonal Influenza Preventative Vaccine PharmacodynamicsClinical Trials (1)
NCT03121339Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults
Phase 1Phase 1
Clinical Trials (1)
NCT00504907Safety Study of Oral BTA9881 to Treat RSV Infection
Phase 1VXA-G1.1-NN
Norovirus InfectionsClinical Trials (1)
NCT07254728A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants
Phase 1VXA-G1.1-NN
Norovirus InfectionsClinical Trials (1)
NCT05213728A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers
Phase 1vapendavir 132 mg capsule
HealthyClinical Trials (1)
NCT02877264A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers
Phase 1VXA-G1.1-NN
Norovirus InfectionsClinical Trials (1)
NCT05212168Norovirus Challenge Study
Phase 1/2VXA-G1.1-NN
Norovirus InfectionsClinical Trials (1)
NCT04875676Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines
Phase 1/220 mg laninamivir octanoate
InfluenzaClinical Trials (1)
NCT02014649Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza
Phase 1/2AP611074
Anogenital WartsClinical Trials (1)
NCT01532102Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts
Phase 1/240 mg Laninamivir Octanoate
InfluenzaClinical Trials (1)
NCT01793883Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza
Phase 2VXA-CoV2-3.1
SARS-CoV2Clinical Trials (1)
NCT06672055A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
Phase 2BTA798
RhinovirusClinical Trials (1)
NCT01175226A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection
Phase 2Vapendavir
AsthmaClinical Trials (1)
NCT02367313A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection
Phase 2BTA-C585 oral capsule
Respiratory Syncytial Virus (RSV) InfectionClinical Trials (1)
NCT02718937Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study
Phase 2AP611074 5% gel
CondylomaClinical Trials (1)
NCT02724254A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
Phase 2Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
Norovirus InfectionsClinical Trials (1)
NCT05626803A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers
Phase 2Vapendavir
RhinovirusClinical Trials (1)
NCT03024177A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection
Phase 2VXA-A1.1
InfluenzaClinical Trials (1)
NCT02918006A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine
Phase 2VXA-CoV2-1.1-S
COVID-19Clinical Trials (1)
NCT05067933A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine
Phase 2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 40 clinical trials
SEC Filings: 2 available
Financials (FY2025)
Revenue
$29M289%
R&D Spend
$74M(259%)9%
Net Income
-$67MCash
$64MHiring Trend
Stable
0
Open Roles
+0
Added
-0
Filled/Removed
Based on last 3 crawl cycles